Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
Terpos E, Migkou M, Christoulas D, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanellias N, Iakovaki M, Panagiotidis I, Ziogas DC, Fotiou D, Kastritis E, Dimopoulos MA. Terpos E, et al. Among authors: fotiou d. Blood Cancer J. 2016 May 27;6(5):e428. doi: 10.1038/bcj.2016.37. Blood Cancer J. 2016. PMID: 27232930 Free PMC article.
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.
Kastritis E, Gavriatopoulou M, Roussou M, Migkou M, Fotiou D, Ziogas DC, Kanellias N, Eleutherakis-Papaiakovou E, Panagiotidis I, Giannouli S, Psimenou E, Marinaki S, Apostolou T, Gakiopoulou H, Tasidou A, Papassotiriou I, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: fotiou d. Am J Hematol. 2017 Jul;92(7):632-639. doi: 10.1002/ajh.24738. Epub 2017 May 26. Am J Hematol. 2017. PMID: 28370245 Free article.
Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.
Kastritis E, Gavriatopoulou M, Roussou M, Fotiou D, Ziogas DC, Migkou M, Eleutherakis-Papaiakovou E, Panagiotidis I, Kanellias N, Psimenou E, Papadopoulou E, Pamboucas C, Manios E, Gakiopoulou H, Ntalianis A, Tasidou A, Giannouli S, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: fotiou d. Blood Cancer J. 2017 Jun 16;7(6):e570. doi: 10.1038/bcj.2017.47. Blood Cancer J. 2017. PMID: 28622303 Free PMC article.
Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit.
Dimopoulos MA, Roussou M, Gavriatopoulou M, Fotiou D, Ziogas DC, Migkou M, Panagiotidis I, Eleutherakis-Papaiakovou E, Kanellias N, Psimenou E, Marinaki S, Bacharaki D, Mparmparoussi D, Matsouka C, Giannouli S, Terpos E, Kastritis E. Dimopoulos MA, et al. Among authors: fotiou d. Blood Cancer J. 2017 Jun 16;7(6):e571. doi: 10.1038/bcj.2017.49. Blood Cancer J. 2017. PMID: 28622304 Free PMC article. Clinical Trial. No abstract available.
Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis.
Eleutherakis-Papaiakovou E, Dimopoulos MA, Kastritis E, Christoulas D, Roussou M, Migkou M, Gavriatopoulou M, Fotiou D, Panagiotidis I, Ziogas DC, Kanellias N, Papadimitriou C, Terpos E. Eleutherakis-Papaiakovou E, et al. Among authors: fotiou d. Bone Marrow Transplant. 2017 Nov;52(11):1537-1542. doi: 10.1038/bmt.2017.172. Epub 2017 Aug 14. Bone Marrow Transplant. 2017. PMID: 28805791
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.
Gavriatopoulou M, Kastritis E, Ntanasis-Stathopoulos I, Fotiou D, Roussou M, Migkou M, Ziogas DC, Kanellias N, Terpos E, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: fotiou d. Blood. 2018 Jan 25;131(4):464-467. doi: 10.1182/blood-2017-10-809293. Epub 2017 Nov 22. Blood. 2018. PMID: 29167176 Free article. No abstract available.
Cardiac and renal complications of carfilzomib in patients with multiple myeloma.
Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Ziogas D, Eleutherakis-Papaiakovou E, Fotiou D, Migkou M, Kanellias N, Panagiotidis I, Ntalianis A, Papadopoulou E, Stamatelopoulos K, Manios E, Pamboukas C, Kontogiannis S, Terpos E, Kastritis E. Dimopoulos MA, et al. Among authors: fotiou d. Blood Adv. 2017 Feb 27;1(7):449-454. doi: 10.1182/bloodadvances.2016003269. eCollection 2017 Feb 28. Blood Adv. 2017. PMID: 29296960 Free PMC article.
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.
Kastritis E, Papassotiriou I, Merlini G, Milani P, Terpos E, Basset M, Akalestos A, Russo F, Psimenou E, Apostolakou F, Roussou M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas DC, Papadopoulou E, Pamboucas C, Dimopoulos MA, Palladini G. Kastritis E, et al. Among authors: fotiou d. Blood. 2018 Apr 5;131(14):1568-1575. doi: 10.1182/blood-2017-12-819904. Epub 2018 Jan 31. Blood. 2018. PMID: 29386197 Free article. Clinical Trial.
How We Manage Patients with Plasmacytomas.
Fotiou D, Dimopoulos MA, Kastritis E. Fotiou D, et al. Curr Hematol Malig Rep. 2018 Jun;13(3):227-235. doi: 10.1007/s11899-018-0452-z. Curr Hematol Malig Rep. 2018. PMID: 29667156 Review.
142 results